You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽隆藥業(002898.SZ):注射用艾司奧美拉唑鈉獲藥品註冊證書
格隆匯 01-07 18:06

格隆匯1月7日丨賽隆藥業(002898.SZ)公佈,公司全資子公司湖南賽隆藥業有限公司於近日獲得國家藥品監督管理局核准簽發的注射用艾司奧美拉唑鈉《藥品註冊證書》。

艾司奧美拉唑是奧美拉唑的單一左旋異構體,屬於質子泵抑制劑(PPI),能有效抑制胃酸分泌,與其它質子泵抑制劑藥物相比,具有快速、持久、穩定抑酸、不良反應少的特點。

注射用艾司奧美拉唑鈉已被列入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2020版)乙類藥品。主要適用於:1.作為當口服療法不適用時,胃食管反流病的替代療法;2.用於口服療法不適用的急性胃或十二指腸潰瘍出血的低危患者(胃鏡下Forrest分級IIc-III);3.用於降低成人胃和十二指腸潰瘍出血內鏡治療後再出血風險;4.預防重症患者應激性潰瘍出血。

根據國家相關政策,公司注射用艾司奧美拉唑鈉以化學藥品新註冊分類4類獲批生產,視同通過仿製藥一致性評價。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account